The Silverstein Foundation For Gba Research
- Assets
- $1.5m
- Revenue
- $49.1k
- Investments
- $64.1k
- Employees
- 0
- Location
- New York, NY
- Founding
- 09/2017
- Data as of
- 12/2022
- EIN
- 82-0656623
Organization Overview
The Silverstein Foundation For Gba Research is located in New York, NY. The organization was established in 2017. According to its NTEE Classification (T30) the organization is classified as: Public Foundations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Silverstein Foundation For Gba Research is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Silverstein Foundation For Gba Research generated $49.1k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 6 years, the organization has seen revenues fall by an average of (55.4%) each year. All expenses for the organization totaled $1.8m during the year ending 12/2022. You can explore the organizations financials more deeply in the financial statements section below.
Since 2017, Silverstein Foundation For Gba Research has awarded 25 individual grants totaling $9,117,011. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990PF
Mission & Program ActivityExcerpts From the 990PF Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
TO RAISE AWARENESS AROUND PARKINSON'S DISEASE ASSOCIATED WITH GBA MUTATIONS; SEE PART III.
Describe the Organization's Program Activity:
Part 3 - Line 4a
SINCE THE LAUNCH OF THE SILVERSTEIN FOUNDATION IN MARCH OF 2017, IT HAS FUNDED OVER 30 GRANTS, RECEIVED DONATIONS FROM OVER 1000 DONORS AND SUPPORTED 7 DIFFERENT THERAPEUTIC APPROACHES, INCLUDING AUTOPHAGY, ANTISENSE OLIGONUCLEOTIDES, GENE THERAPY, ALPHA SYNUCLEIN DEGRADERS, GLUCOCEREBROSIDASE ACTIVATORS, SUBSTRATE REDUCTION THERAPY, AND AUTOLOGOUS INDUCED PLURIPOTENT STEM CELLS TO ACCELERATE RESEARCH AND CLINICAL TRIALS TO BRING NEW THERAPEUTIC OPTIONS TO PATIENTS. SEE SCHEDULE O.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Jonathan Silverstein President / Secretary | 2 | $0 | |
Natalie Silverstein Vice President / Treasurer | 1 | $0 | |
Geoffrey Levin Board Member | 1 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Contributions, Gifts, Grants & Similar | $26,818 |
| Interest on Savings | $0 |
| Dividends & Interest | $22,257 |
| Net Rental Income | $0 |
| Net Gain on Sale of Assets | $0 |
| Capital Gain Net Income | $0 |
| Net ST Capital Gain | $0 |
| Income Modifications | $0 |
| Profit on Inventory Sales | $0 |
| Other Income | $0 |
| Total Revenue | $49,075 |
| Statement of Expenses | |
|---|---|
| Compensation of officers, directors, trustees, etc | $0 |
| Other employee salaries and wages | $0 |
| Pension plans, employee benefits | $0 |
| Interest | $0 |
| Taxes | $0 |
| Depreciation | $0 |
| Occupancy | $0 |
| Travel, conferences, and meetings | $0 |
| Printing and publications | $0 |
| Other expenses | $3,808 |
| Total operating and administrative expenses | $45,512 |
| Contributions, gifts, grants paid | $1,797,500 |
| Total expenses and disbursements | $1,843,012 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $1,412,230 |
| Savings and temporary cash investments | $0 |
| Net Accounts receivable | $0 |
| Net Pledges Receivable | $0 |
| Grants receivable | $0 |
| Receivables from Officers, Directors, or Controlling Persons | $0 |
| Net other notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Investments - land, buildings, equipment | $0 |
| Investments—mortgage loans | $0 |
| Investments—other | $0 |
| Net Land, buildings, and equipment | $0 |
| Other assets | $0 |
| Total assets | $1,476,308 |
| Accounts payable and accrued expenses | $18,915 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Mortgages and other notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $18,915 |
Grants Awarded
Over the last fiscal year, The Silverstein Foundation For Gba Research has awarded $2,650,000 in support to 5 organizations.
| Grant Recipient | Amount |
|---|---|
THE NEW YORK STEM CELL FOUNDATION PURPOSE: DRUG DISCOVERY FOR PARKINSON'S WITH GBA. | $1,372,500 |
LYSOWAY THERAPEUTICS PURPOSE: EVALUATING THE THERAPEUTIC EFFECTS OF TRPML1 AND TMEM175 AGONISTS ON GBA-DEFICIENT PARKINSON'S DISEASE MODELS. | $225,000 |
THE NEW YORK STEM CELL FOUNDATION PURPOSE: DRUG DISCOVERY FOR PARKINSON'S WITH GBA | $627,500 |
MICHAEL J FOX FOUNDATION MODAG PURPOSE: FOLLOW-UP STUDY OF A DRUG (ANLE138B) - GOAL IS TO STOP THE PARKINSON'S PROTEIN ALPHA-SYNUCLEIN (A-SYN) FROM CLUMPING TOGETHER. | $200,000 |
CURASEN THERAPEUTICS PURPOSE: GENOTYPING AND BIOMARKER ANALYSES IN CLINICAL STUDY CLIN-015 | $225,000 |